Good evening :)

Sectoral Fund - Pharma & Health Care

Sectoral Funds - Pharma & Health Care are equity schemes that majorly invest in healthcare sector companies. It will give exposure to entire healthcare sector which comprised a wide range of companies involved in medical services, medical equipments, drugs and medical insurance.

  • ⏱ Horizon: Long
  • 🔢 Total funds: 18
  • 💰 Total AUM: 33,451 Cr

Best performing Sectoral Fund - Pharma & Health Care

NameAUM (Cr)Exp Ratio (%)1Y Return3Y CAGR5Y CAGR
ICICI Pru Pharma Healthcare & Diagnostics (P.H.D) Fund6,668.951.0514.41%29.51%17.53%
SBI Healthcare Opp Fund4,323.290.9211.82%27.63%17.16%
Mirae Asset Healthcare Fund2,939.230.5118.63%27.35%16.60%
Tata India Pharma & Healthcare Fund1,325.190.7210.98%25.50%15.73%
DSP Healthcare Fund2,891.760.6210.74%24.20%15.60%
UTI Healthcare Fund1,143.581.3615.65%27.55%15.46%
Aditya Birla SL Pharma & Healthcare Fund900.871.0215.15%26.03%14.70%
Nippon India Pharma Fund8,365.400.9311.88%24.76%14.61%
LIC MF Healthcare Fund78.300.6414.30%24.48%12.67%
ITI Pharma & Healthcare Fund211.300.479.29%23.42%—%

To view more Sectoral Fund - Pharma & Health Care

Visit ScreenerScreener

Overview of Sectoral Fund - Pharma & Health Care

ICICI Pru Pharma Healthcare & Diagnostics (P.H.D) Fund
  • AUM
    ₹ 6,668.95 Cr.
  • Expense Ratio
    1.05%
  • 5Y CAGR
    17.53%
Performance
The fund's annualised performance has been 21.2% since inception.
Risk
The fund has been categorised as Very High by SEBI and has a standard deviation of 13.7% vs its category average of 12.75%.
Composition
Small Cap makes up for the majority of the fund at 36.52% along with the largest allocation towards Pharmaceuticals at 82.8%.
SBI Healthcare Opp Fund
  • AUM
    ₹ 4,323.29 Cr.
  • Expense Ratio
    0.92%
  • 5Y CAGR
    17.16%
Performance
The fund's annualised performance has been 17.66% since inception.
Risk
The fund has been categorised as Very High by SEBI and has a standard deviation of 11.99% vs its category average of 12.75%.
Composition
Mid Cap makes up for the majority of the fund at 38.19% along with the largest allocation towards Pharmaceuticals at 64.35%.
Mirae Asset Healthcare Fund
  • AUM
    ₹ 2,939.23 Cr.
  • Expense Ratio
    0.51%
  • 5Y CAGR
    16.6%
Performance
The fund's annualised performance has been 21.83% since inception.
Risk
The fund has been categorised as Very High by SEBI and has a standard deviation of 13.25% vs its category average of 12.75%.
Composition
Mid Cap makes up for the majority of the fund at 45.81% along with the largest allocation towards Pharmaceuticals at 76.5%.
Tata India Pharma & Healthcare Fund
  • AUM
    ₹ 1,325.19 Cr.
  • Expense Ratio
    0.72%
  • 5Y CAGR
    15.73%
Performance
The fund's annualised performance has been 13.43% since inception.
Risk
The fund has been categorised as Very High by SEBI and has a standard deviation of 11.71% vs its category average of 12.75%.
Composition
Small Cap makes up for the majority of the fund at 40.25% along with the largest allocation towards Pharmaceuticals at 58.7%.
DSP Healthcare Fund
  • AUM
    ₹ 2,891.76 Cr.
  • Expense Ratio
    0.62%
  • 5Y CAGR
    15.6%
Performance
The fund's annualised performance has been 22.26% since inception.
Risk
The fund has been categorised as Very High by SEBI and has a standard deviation of 12.13% vs its category average of 12.75%.
Composition
Small Cap makes up for the majority of the fund at 39.77% along with the largest allocation towards Pharmaceuticals at 65.25%.
UTI Healthcare Fund
  • AUM
    ₹ 1,143.58 Cr.
  • Expense Ratio
    1.36%
  • 5Y CAGR
    15.46%
Performance
The fund's annualised performance has been 15.98% since inception.
Risk
The fund has been categorised as Very High by SEBI and has a standard deviation of 12.39% vs its category average of 12.75%.
Composition
Small Cap makes up for the majority of the fund at 41.09% along with the largest allocation towards Pharmaceuticals at 70.82%.
Aditya Birla SL Pharma & Healthcare Fund
  • AUM
    ₹ 900.87 Cr.
  • Expense Ratio
    1.02%
  • 5Y CAGR
    14.7%
Performance
The fund's annualised performance has been 20.96% since inception.
Risk
The fund has been categorised as Very High by SEBI and has a standard deviation of 11.85% vs its category average of 12.75%.
Composition
Mid Cap makes up for the majority of the fund at 34.26% along with the largest allocation towards Pharmaceuticals at 77.31%.
Nippon India Pharma Fund
  • AUM
    ₹ 8,365.40 Cr.
  • Expense Ratio
    0.93%
  • 5Y CAGR
    14.61%
Performance
The fund's annualised performance has been 17.53% since inception.
Risk
The fund has been categorised as Very High by SEBI and has a standard deviation of 12.26% vs its category average of 12.75%.
Composition
Mid Cap makes up for the majority of the fund at 41.04% along with the largest allocation towards Pharmaceuticals at 75.25%.
LIC MF Healthcare Fund
  • AUM
    ₹ 78.30 Cr.
  • Expense Ratio
    0.64%
  • 5Y CAGR
    12.67%
Performance
The fund's annualised performance has been 18.56% since inception.
Risk
The fund has been categorised as Very High by SEBI and has a standard deviation of 12.26% vs its category average of 12.75%.
Composition
Mid Cap makes up for the majority of the fund at 32.23% along with the largest allocation towards Pharmaceuticals at 68.81%.
ITI Pharma & Healthcare Fund
  • AUM
    ₹ 211.30 Cr.
  • Expense Ratio
    0.47%
  • 5Y CAGR
    0%
Performance
The fund's annualised performance has been 14.23% since inception.
Risk
The fund has been categorised as Very High by SEBI and has a standard deviation of 13.27% vs its category average of 12.75%.
Composition
Mid Cap makes up for the majority of the fund at 40.97% along with the largest allocation towards Pharmaceuticals at 70.1%.
This compilation has been made as and by way of an update from the publicly available sources of information.This compilation is provided for information purposes only and is not intended to be relied upon by any party as the basis of any decision.

While every effort has been made to take due care in publishing this compilation and to avoid errors or omissions, this compilation is published with a condition and understanding that the Anchorage Technologies Private Limited (ATPL) shall not be responsible for any damages, compensation or loss or action taken or abstained to be taken on the basis of this article/commentary to any person whomsoever.

Investing in Mutual Funds,Stocks/ETFs (Exchange Traded Funds) and securities are subject to market risk. Please read all the related documents carefully before investing. Investors should consider all risk factors and consult their financial advisor before investing. Representations are not indicative of future results.